Leadership Overview
GRIFOLS has 4 executives leading key functions including strategy, commercial operations, medical affairs, and biopharma.
Driven by a commitment to improving health, GRIFOLS operates as a global healthcare leader, dedicated to enhancing people's well-being worldwide through innovative plasma-derived medicines and a strong focus on ethical practices and patient safety.
Driven by a commitment to improving health, GRIFOLS operates as a global healthcare leader, dedicated to enhancing people's well-being worldwide through innovative plasma-derived medicines and a strong focus on ethical practices and patient safety.
Leadership Roles at GRIFOLS
Christopher Healey - President
Christopher Healey, the President at GRIFOLS, directs the overarching strategic vision and operational execution across the global enterprise. Healey guides the company's expansion into new markets, ensuring alignment with Grifols' mission to improve health and well-being. This leadership role involves fostering innovation within the Bioscience, Diagnostic, Hospital, and Bio Supplies divisions, driving growth and maintaining Grifols' position as an industry reference for quality and safety. Healey's strategic direction supports the company's long-term, sustainable, and responsible perspective across the entire value chain. By focusing on donor and patient well-being, Christopher Healey ensures that all initiatives contribute directly to enhancing people's lives globally. The President's oversight extends to cultivating a diverse and skilled team, recognizing its critical importance for future success and reinforcing Grifols' commitment to ethical operations.
William Zabel - Sales & Commercial Operations President (North America)
William Zabel, the Sales & Commercial Operations President (North America) at GRIFOLS, spearheads all sales initiatives and commercial strategies within the vital North American region. Zabel drives revenue growth and market penetration for Grifols' diverse portfolio of plasma-derived medicines and healthcare solutions. This executive oversees the intricate network of sales teams and commercial operations, ensuring seamless product delivery and exceptional customer engagement. By optimizing sales channels and commercial strategies, William Zabel directly contributes to Grifols' objective of being a global leader in its markets. The focus remains on expanding market reach and reinforcing Grifols' reputation for quality and innovation in one of its most significant operational territories. Zabel's leadership ensures that the company's commitment to improving health and well-being is effectively translated into commercial success across North America.
Roland Wandeler - President Biopharma
Roland Wandeler, the President Biopharma at GRIFOLS, directs the strategic growth and operational excellence of the Biopharma division, a cornerstone of Grifols' plasma-derived medicines business. Wandeler spearheads initiatives focused on expanding the reach and impact of Grifols' innovative therapies, ensuring they meet the needs of patients worldwide. This leadership role involves driving research and development efforts, optimizing manufacturing processes, and forging key partnerships to enhance the division's market position. Roland Wandeler's focus on innovation and quality directly supports Grifols' commitment to improving health and well-being. By leading the Biopharma division, Wandeler plays a crucial part in Grifols' mission to be a global leader, emphasizing a long-term, sustainable, and responsible perspective in all operations and product development.
Marilyn Rosa - Chief Medical Officer & Global Senior VP, Plasma Quality & Regulatory Affairs
Marilyn Rosa, the Chief Medical Officer & Global Senior VP, Plasma Quality & Regulatory Affairs at GRIFOLS, governs the critical medical strategy and ensures the highest standards of plasma quality and regulatory compliance worldwide. Rosa leads the scientific and medical affairs functions, providing essential expertise that underpins Grifols' product development and patient safety initiatives. This senior leadership position involves meticulous oversight of all regulatory submissions and adherence to global health authority requirements, safeguarding the integrity of Grifols' plasma-derived medicines. Marilyn Rosa's dedication to quality ensures that Grifols maintains its industry reference status for safety and innovation. By championing rigorous quality control and robust regulatory frameworks, Rosa directly supports the company's mission to improve the health and well-being of people globally, reinforcing Grifols' ethical approach and long-term sustainable perspective.
Explore Leadership Teams in Blood & Organ Banks
Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of our healthcare partners nationally. We provide innovative, value-added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts across Versiti result in improved patient outcomes, expanded access to care, and cost efficiencies for healthcare systems nationwide.
Company Leadership DM
BB
JF
CM
Novavax, Inc. is a biotechnology company incorporated in 1987 and headquartered in Gaithersburg, Maryland, focused on discovering, developing, and commercializing vaccines to protect against serious infectious diseases. The company's proprietary technology platform combines a recombinant protein approach, nanoparticle technology, and a patented adjuvant to enhance immune response. Novavax's pipeline spans vaccine candidates targeting infectious diseases including COVID-19, influenza, respiratory syncytial virus, malaria, shingles, and other pathogens, with ongoing exploration of its adjuvant platform in oncology. The company maintains a strategic partnership with Sanofi for COVID-19 vaccine commercialization and has established licensing and collaboration agreements with major global pharmaceutical companies. Novavax trades on the NASDAQ under the ticker symbol NVAX.
Company Leadership RM
BL
LF
信达生物制药 specializes in the research, development, and production of innovative biopharmaceuticals. The company focuses on providing advanced therapies for various diseases, particularly in oncology and autoimmune disorders. Its intended clients include healthcare providers, hospitals, and patients seeking effective treatment options. With a commitment to quality and innovation, 信达生物制药 aims to improve patient outcomes through its cutting-edge products.
Company Leadership HX
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Company Leadership HA
MP
KL
SL
Frequently Asked Questions Regarding GRIFOLS Top Executives and Leadership Team
